Evidence mapPaperPMID 30368741Full record

ArticleBreast cancer research and treatment2019

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.

Katherine R Walter, Marvella E Ford, Mathew J Gregoski, Rita M Kramer, Kendrea D Knight, Laura Spruill, Lourdes M Nogueira, Bradley A Krisanits, Van Phan, Amanda C La Rue and 17 more

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Dietary Advanced Glycation End-Products and Mortality after Breast Cancer in the Women's Health Initiative.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 2 countries.

Katherine R WalterDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Marvella E FordDepartment of Public Health Sciences, MUSC, Charleston, SC, USA. fordmar@musc.edu.
Mathew J GregoskiDepartment of Exercise Science, College of Arts and Sciences, Campbell University, Buies Creek, NC, USA.
Rita M KramerHollings Cancer Center, MUSC, Charleston, SC, USA.
Kendrea D KnightDepartment of Public Health Sciences, MUSC, Charleston, SC, USA.
Laura SpruillDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Lourdes M NogueiraDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Bradley A KrisanitsDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Van PhanDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Amanda C La RueDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Michael B LillyDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Stefan AmbsLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
King ChanCancer Research Technology Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD, USA.
Tonya F TurnerDietetic Services, MUSC, Charleston, SC, USA.
Heidi VarnerDepartment of Public Health Sciences, MUSC, Charleston, SC, USA.
Shweta SinghDepartment of Public Health Sciences, MUSC, Charleston, SC, USA.
Jaime UribarriDepartment of Medicine/Renal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Elizabeth Garrett-MayerDepartment of Public Health Sciences, MUSC, Charleston, SC, USA.
Kent E ArmesonDepartment of Public Health Sciences, MUSC, Charleston, SC, USA.
Ebony J HiltonDepartment of Anesthesia and Perioperative Medicine, MUSC, Charleston, SC, USA.
Mark J ClairDepartment of Medicine, Division of Cardiology, MUSC, Charleston, SC, USA.
Marian H TaylorDepartment of Medicine, Division of Cardiology, MUSC, Charleston, SC, USA.
Andrea M AbbottDepartment of Surgery, MUSC, Charleston, SC, USA.
Victoria J FindlayDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Lindsay L PetersonWashington University School of Medicine, St. Louis, MO, USA.
Gayenell MagwoodCollege of Nursing, MUSC, Charleston, SC, USA.
David P TurnerDepartment of Pathology & Laboratory Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA. turnerda@musc.edu.ORCID http://orcid.org/0000-0003-3667-8844
Medical University of South Carolina · USMUSC Hollings Cancer Center · USAcademy of Nutrition and Dietetics · USCampbell University · USIcahn School of Medicine at Mount Sinai · USLeidos (United States) · USNational Cancer Institute · USUniversity of Charleston · USWashington University in St. Louis · US

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · MEDICAL UNIVERSITY OF SOUTH CAROLINA · 2025 to 2025
$2.4M
Novel Markers for Disease Outcome in Breast CancerZIABC010887 · DIVISION OF BASIC SCIENCES - NCI · 2025 to 2025
$721k
NCI NIH HHS CA157071NCI NIH HHS CA176135NCI NIH HHS CA210962NCI NIH HHS P20 CA157071NCI NIH HHS P30 CA138313NCI NIH HHS R21 CA176135NCI NIH HHS U54 CA210962NCI NIH HHS U54 CA210963
6 · The paper itself

Abstract

purposeLifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the body which is associated with disease phenotypes through modification of the genome, protein crosslinking/dysfunction, and aberrant cell signaling. Given the links between lifestyle, AGEs, and disease, we examined the association between dietary-AGEs and breast cancer.

methodsWe evaluated AGE levels in bio-specimens from estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer patients, examined their role in therapy resistance, and assessed the ability of lifestyle intervention to reduce circulating AGE levels in ER+ breast cancer survivors.

resultsAn association between ER status and AGE levels was observed in tumor and serum samples. AGE treatment of ER+ breast cancer cells altered ERα phosphorylation and promoted resistance to tamoxifen therapy. In a proof of concept study, physical activity and dietary intervention was shown to be viable options for reducing circulating AGE levels in breast cancer survivors.

conclusionsThere is a potential prognostic and therapeutic role for lifestyle derived AGEs in breast cancer. Given the potential benefits of lifestyle intervention on incidence and mortality, opportunities exist for the development of community health and nutritional programs aimed at reducing AGE exposure in order to improve breast cancer prevention and treatment outcomes.

Indexed as

Life StyleAgedAntineoplastic Agents, HormonalBiomarkersBreast NeoplasmsCancer SurvivorsCell Line, TumorCombined Modality TherapyDrug Resistance, NeoplasmFemaleGlycation End Products, AdvancedHumansMiddle AgedNeoplasm GradingNeoplasm StagingReceptors, EstrogenAntineoplastic Agents, HormonalBiomarkersGlycation End Products, AdvancedReceptors, EstrogenTamoxifenAdvanced glycation end productBreast cancerEstrogen receptorLifestyle interventionTamoxifen resistance

Identifiers

PMID30368741
PMCPMC6394600
OpenAlexW2898154941

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.